Mirum Pharmaceuticals Inc said
on Wednesday that the US Food and Drug Administration has
approved its drug to treat itching in patients with Alagille
syndrome, making it the first approved therapy for treating
symptoms of the genetic disorder.
(Reporting by Mrinalika Roy and Bhanvi Satija in Bengaluru;
Editing by Shinjini Ganguli)